";s:4:"text";s:4158:" Reactivation of hepatitis B virus (HBV) is a syndrome characterized by the reappearance of HBV particles in patients with previously resolved HBV or an increase in HBV viremia in patients with previously inactive chronic hepatitis B (CHB).
Patients with CHB have a higher risk than patients with resolved HBV.The final step in preventing HBV reactivation is tailoring management based on risk stratification. As a result, this technique has fewer side effects than standard chemotherapy. The guideline … Sometimes, the health care team will change the chemotherapy doses or they may delay or stop the treatment to prevent the side effects from getting worse. Adjustments for the quality of life were not performed. Hepatology.
This is why chemotherapy can lead to side effects, such as hair loss, mouth sores, loss of appetite, nausea and vomiting, and diarrhea. To increase the generalizability of our model, we varied all event probabilities and costs (Tables Using the baseline assumptions derived from published literature, we extrapolated the clinical costs and outcomes to a cohort of 1000 patients, with 500 in each treatment strategy group (Table Lamivudine prophylaxis was the most cost‐effective strategy in a 1‐way sensitivity analysis for most varied variables (Tables Hepatitis B reactivation poses a significant risk to patients undergoing chemotherapy. Even the drugs that have shown some effectiveness are able to shrink fewer than 1 in 5 tumors, and the effect does not last long.Because of these poor results, doctors sometimes inject the chemotherapy drugs directly into the hepatic artery.
In the second strategy, patients received lamivudine only if there was clinical evidence for HBV reactivation. HBV life cycle.